| scholarly article | Q13442814 |
| P2093 | author name string | Michael Hensel | |
| Kim Busch | |||
| Nathalie Böhles | |||
| P2860 | cites work | New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. | Q53579124 |
| Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. | Q53588316 | ||
| Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. | Q54572055 | ||
| Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge | Q57924808 | ||
| Field Trial of Oral Cholera Vaccines in Bangladesh: Results of One Year of Follow-Up | Q57926677 | ||
| Similarity of the VP4 protein of human rotavirus strain 116E to that of the bovine B223 strain | Q64135787 | ||
| Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. | Q64948328 | ||
| Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E | Q72538917 | ||
| Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine | Q72578133 | ||
| Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses | Q73510912 | ||
| A newborn mouse model for the study of intestinal pathogenesis of shigellosis | Q73546914 | ||
| Growth of rotaviruses in continuous human and monkey cell lines that vary in their expression of integrins | Q74198319 | ||
| Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle | Q74335025 | ||
| The World Health Report 2006: working together for health | Q79441206 | ||
| Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 | ||
| [Physiopathology of Rotavirus diarrhea] | Q81502312 | ||
| Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice | Q81964639 | ||
| Cholera vaccines: WHO position paper | Q83941810 | ||
| Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks | Q21090119 | ||
| Thimerosal-Derived Ethylmercury Is a Mitochondrial Toxin in Human Astrocytes: Possible Role of Fenton Chemistry in the Oxidation and Breakage of mtDNA | Q21296653 | ||
| Phase and antigenic variation in bacteria | Q24561666 | ||
| Wanted, dead or alive: New viral vaccines | Q27489979 | ||
| The virosome concept for influenza vaccines | Q28262476 | ||
| Field Assessment of a Novel Household-Based Water Filtration Device: A Randomised, Placebo-Controlled Trial in the Democratic Republic of Congo | Q28749319 | ||
| Simple Sari Cloth Filtration of Water Is Sustainable and Continues To Protect Villagers from Cholera in Matlab, Bangladesh | Q29398228 | ||
| Multi-locus variable number tandem repeat analysis of 7th pandemic Vibrio cholerae | Q30417198 | ||
| Enteric infections, diarrhea, and their impact on function and development | Q30443288 | ||
| Novel vaccine strategies to T-independent antigens | Q30726038 | ||
| Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area | Q30851263 | ||
| Household water chlorination reduces incidence of diarrhea among under-five children in rural Ethiopia: a cluster randomized controlled trial | Q31142709 | ||
| Chloride channel inhibition by a red wine extract and a synthetic small molecule prevents rotaviral secretory diarrhoea in neonatal mice | Q33723721 | ||
| The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers | Q33768926 | ||
| Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. | Q33892877 | ||
| Vaccination strategies to combat an infectious globe: oral cholera vaccines. | Q33900135 | ||
| Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine | Q33928456 | ||
| Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans | Q34003433 | ||
| Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults | Q34006013 | ||
| Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults | Q34008338 | ||
| Cholera toxin - a foe & a friend. | Q34026162 | ||
| Cholera vaccines | Q34033611 | ||
| Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E | Q34077813 | ||
| Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults | Q34120926 | ||
| Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers | Q34194587 | ||
| Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference | Q34207204 | ||
| 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis | Q34227701 | ||
| Detection of PCV-2 DNA in stool samples from infants vaccinated with RotaTeq® | Q34271511 | ||
| Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review. | Q34374858 | ||
| Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity | Q34394744 | ||
| Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice | Q34429033 | ||
| Shigellosis | Q34557460 | ||
| Vibrio cholerae: lessons for mucosal vaccine design | Q34562952 | ||
| Isolation and genomic characterization of SfI, a serotype-converting bacteriophage of Shigella flexneri | Q34588634 | ||
| Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway | Q34990010 | ||
| An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines | Q35100779 | ||
| Towards an understanding of the adjuvant action of aluminium | Q35138579 | ||
| Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides | Q35335585 | ||
| Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. | Q35530313 | ||
| Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis | Q35532405 | ||
| Technologies for enhanced efficacy of DNA vaccines | Q35802958 | ||
| Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh | Q35940653 | ||
| Construction and Evaluation of a Safe, Live, Oral Vibrio cholerae Vaccine Candidate, IEM108 | Q36045133 | ||
| Immunity, inflammation, and allergy in the gut. | Q36080132 | ||
| Particulate delivery systems for biodefense subunit vaccines | Q36151625 | ||
| Campylobacter polysaccharide capsules: virulence and vaccines | Q36159521 | ||
| Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. | Q36172686 | ||
| Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. | Q36210208 | ||
| Mucosal vaccines: the promise and the challenge | Q36402244 | ||
| Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. | Q36422508 | ||
| Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review | Q36443591 | ||
| The lipopolysaccharide of Shigella bacteria as a virulence factor | Q36654698 | ||
| Report of the 1966-67 cholera vaccine trial in rural East Pakistan | Q36785801 | ||
| Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 | ||
| Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens | Q36913862 | ||
| The pneumococcus: epidemiology, microbiology, and pathogenesis | Q36938477 | ||
| Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients. | Q37064863 | ||
| Characterization of rotavirus strains from newborns in New Delhi, India | Q37089007 | ||
| Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. | Q37123967 | ||
| Shigellosis: the current status of vaccine development | Q37151797 | ||
| New-generation vaccines against cholera | Q37953796 | ||
| Cholera-like enterotoxins and Regulatory T cells | Q37954306 | ||
| Mucosal vaccine design and delivery | Q38004587 | ||
| Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions | Q38061474 | ||
| Innate cellular responses to rotavirus infection. | Q38088957 | ||
| Accelerating next-generation vaccine development for global disease prevention | Q38110775 | ||
| Recommendations for rotavirus vaccine | Q38112890 | ||
| Genetic diversity of G1P[8] rotavirus VP7 and VP8* antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq® vaccine | Q38119831 | ||
| The state-of-the-art of approved and under-development cholera vaccines | Q38120924 | ||
| Edible transgenic plant vaccines for different diseases | Q38135507 | ||
| The value of and challenges for cholera vaccines in Africa | Q38150312 | ||
| Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants | Q39044644 | ||
| Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer | Q39084400 | ||
| Diarrheal disease during Operation Desert Shield | Q39090383 | ||
| Aluminium based adjuvants and their effects on mitochondria and lysosomes of phagocytosing cells | Q39102474 | ||
| A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. | Q39158452 | ||
| Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile | Q39252440 | ||
| Further characterization of Shigella sonnei live vaccine candidates WRSs2 and WRSs3-plasmid composition, invasion assays and Sereny reactions | Q39461241 | ||
| Generation and characterization of a live attenuated enterotoxigenic Escherichia coli combination vaccine expressing six colonization factors and heat-labile toxin subunit B. | Q39657777 | ||
| Effectiveness of mass oral cholera vaccination in Beira, Mozambique | Q39708620 | ||
| Chapter 6 Isolation and Characterization of Chromatin Subunits | Q39769222 | ||
| Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: preclinical evidence of immunogenicity and protection | Q40444589 | ||
| Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. | Q40469794 | ||
| Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines | Q40471020 | ||
| Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial | Q40501431 | ||
| Antioxidant effect of zinc in humans | Q40510598 | ||
| Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers | Q42284964 | ||
| Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. | Q43432983 | ||
| TLP01, an mshA mutant of Vibrio cholerae O139 as vaccine candidate against cholera | Q43642194 | ||
| Infectious diarrhea: new pathogens and new challenges in developed and developing areas | Q44303359 | ||
| Predictive markers of safety and immunogenicity of adjuvanted vaccines | Q45057515 | ||
| Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. | Q45990647 | ||
| Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation | Q46652410 | ||
| An outbreak of El Tor cholera in Kavre district, Nepal | Q46895981 | ||
| Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine | Q46938617 | ||
| Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. | Q47832226 | ||
| More on RotaShield and intussusception: the role of age at the time of vaccination. | Q50767129 | ||
| Background paper to the recommendation for routine rotavirus vaccination of infants in Germany. | Q52883374 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1522-1535 | |
| P577 | publication date | 2014-05-26 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Vaccines against human diarrheal pathogens: current status and perspectives | |
| P478 | volume | 10 |
| Q59135204 | Clinical features, risk factors, and impact of antibiotic treatment of diarrhea caused by Shigella in children less than 5 years in Manhiça District, rural Mozambique |
| Q35896237 | Combination vaccines against diarrheal diseases |
| Q26783111 | Plant-made oral vaccines against human infectious diseases-Are we there yet? |
| Q38849581 | Recent advances in the production of recombinant subunit vaccines in Pichia pastoris |
Search more.